Zacks Investment Research upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a hold rating to a buy rating in a research report report published on Saturday morning, Zacks.com reports. The brokerage currently has $3.75 price target on the biotechnology company’s stock.
According to Zacks, “Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany. “
Several other research firms have also recently commented on PIRS. ValuEngine upgraded Pieris Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, April 5th. HC Wainwright reiterated a buy rating and issued a $5.00 price target on shares of Pieris Pharmaceuticals in a research note on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $4.38.
Shares of NASDAQ PIRS opened at $3.11 on Friday. Pieris Pharmaceuticals has a 1-year low of $2.39 and a 1-year high of $6.94. The stock has a market capitalization of $166.62 million, a PE ratio of -6.22 and a beta of 1.88.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.05). Pieris Pharmaceuticals had a negative return on equity of 54.54% and a negative net margin of 91.93%. The business had revenue of $4.91 million during the quarter, compared to analyst estimates of $6.92 million. As a group, research analysts expect that Pieris Pharmaceuticals will post -0.81 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in PIRS. Citadel Advisors LLC lifted its stake in shares of Pieris Pharmaceuticals by 162.7% in the third quarter. Citadel Advisors LLC now owns 193,617 shares of the biotechnology company’s stock worth $1,084,000 after acquiring an additional 119,910 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in shares of Pieris Pharmaceuticals by 18.6% in the third quarter. TIAA CREF Investment Management LLC now owns 334,082 shares of the biotechnology company’s stock worth $1,871,000 after acquiring an additional 52,302 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Pieris Pharmaceuticals by 13.6% in the third quarter. Vanguard Group Inc. now owns 370,616 shares of the biotechnology company’s stock worth $2,076,000 after acquiring an additional 44,335 shares in the last quarter. Marshall Wace LLP raised its stake in Pieris Pharmaceuticals by 589.9% during the third quarter. Marshall Wace LLP now owns 161,078 shares of the biotechnology company’s stock valued at $902,000 after buying an additional 137,730 shares in the last quarter. Finally, Vanguard Group Inc raised its stake in Pieris Pharmaceuticals by 13.6% during the third quarter. Vanguard Group Inc now owns 370,616 shares of the biotechnology company’s stock valued at $2,076,000 after buying an additional 44,335 shares in the last quarter. Institutional investors and hedge funds own 70.73% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More: Trading Strategy Examples and Plans
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.